MA51881A - Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7 - Google Patents

Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7

Info

Publication number
MA51881A
MA51881A MA051881A MA51881A MA51881A MA 51881 A MA51881 A MA 51881A MA 051881 A MA051881 A MA 051881A MA 51881 A MA51881 A MA 51881A MA 51881 A MA51881 A MA 51881A
Authority
MA
Morocco
Prior art keywords
potassian
channel
alcohol derivatives
derivatives used
opening agents
Prior art date
Application number
MA051881A
Other languages
English (en)
Other versions
MA51881B1 (fr
Inventor
Shu Hui Chen
Debasis Das
Jian Hong
Mario Rottländer
Anette Graven Sams
Xiaofang Wang
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA51881A publication Critical patent/MA51881A/fr
Publication of MA51881B1 publication Critical patent/MA51881B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
MA51881A 2018-02-20 2018-02-20 Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7 MA51881B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/054057 WO2019161877A1 (fr) 2018-02-20 2018-02-20 Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7

Publications (2)

Publication Number Publication Date
MA51881A true MA51881A (fr) 2020-12-30
MA51881B1 MA51881B1 (fr) 2023-08-31

Family

ID=61557232

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51881A MA51881B1 (fr) 2018-02-20 2018-02-20 Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7

Country Status (12)

Country Link
EP (2) EP4241843B1 (fr)
JP (1) JP7121144B2 (fr)
CN (2) CN116589375A (fr)
ES (2) ES3032221T3 (fr)
HR (1) HRP20230808T1 (fr)
HU (1) HUE063567T2 (fr)
MA (1) MA51881B1 (fr)
MD (1) MD3755684T2 (fr)
PL (1) PL3755684T3 (fr)
RS (1) RS64479B1 (fr)
SM (1) SMT202300235T1 (fr)
WO (1) WO2019161877A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
RS66130B1 (sr) * 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
CN114206328B (zh) * 2019-08-02 2024-09-17 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) * 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
CN115461327A (zh) 2020-04-29 2022-12-09 爱杜西亚药品有限公司 螺脲衍生物
AU2021295422A1 (en) 2020-06-25 2023-02-23 Idorsia Pharmaceuticals Ltd Cyclobutyl-urea derivatives
WO2024121779A1 (fr) 2022-12-09 2024-06-13 Pfizer Inc. Inhibiteurs de la protéase de type papaïne (plpro)
IL325387A (en) * 2023-06-27 2026-02-01 Saniona As KV7 modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092526A1 (fr) 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Kcnq5, canal potassium humain, procedes et compositions de ce dernier
WO2001096540A2 (fr) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Exosite de la protease de l'hepatite c servant a la mise au point d'inhibiteurs
WO2004047738A2 (fr) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Amides arylcyclopropylcarboxyliques utilises en tant qu'agents d'ouverture des canaux potassiques
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TWI453013B (zh) 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
WO2007104717A1 (fr) * 2006-03-15 2007-09-20 Neurosearch A/S Quinazolinones et leur application en tant qu'agents activant le canal potassique
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
TW201024286A (en) * 2008-11-27 2010-07-01 Neurosearch As Novel compounds
AU2011275393B2 (en) * 2010-07-08 2014-04-10 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
HK1216095A1 (zh) 2012-12-10 2016-10-14 H. Lundbeck A/S 烟碱乙酰胆碱受体的新的正向别构调节剂
WO2014145852A2 (fr) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridine-2-yl amides en tant que d'activateurs du canal kv7
SMT202300362T1 (it) 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
CN105663136A (zh) * 2016-01-15 2016-06-15 河北中医学院 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用

Also Published As

Publication number Publication date
EP4241843A2 (fr) 2023-09-13
EP3755684C0 (fr) 2023-07-12
EP3755684A1 (fr) 2020-12-30
EP4241843C0 (fr) 2025-05-21
ES3032221T3 (en) 2025-07-16
JP2021519814A (ja) 2021-08-12
CN111727182B (zh) 2023-05-26
HUE063567T2 (hu) 2024-01-28
HRP20230808T1 (hr) 2023-11-10
BR112019021960A2 (pt) 2020-08-25
MA51881B1 (fr) 2023-08-31
JP7121144B2 (ja) 2022-08-17
EP4241843A3 (fr) 2023-09-27
EP3755684B1 (fr) 2023-07-12
CN116589375A (zh) 2023-08-15
SMT202300235T1 (it) 2023-11-13
MD3755684T2 (ro) 2023-11-30
WO2019161877A1 (fr) 2019-08-29
RS64479B1 (sr) 2023-09-29
EP4241843B1 (fr) 2025-05-21
CN111727182A (zh) 2020-09-29
PL3755684T3 (pl) 2023-11-06
ES2951656T3 (es) 2023-10-24

Similar Documents

Publication Publication Date Title
MA51881A (fr) Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
MA54452A (fr) Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
EP3442973A4 (fr) Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54157A (fr) Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3554506A4 (fr) Dérivés d'hétéroaryle bycyclique en tant que potentialisateurs du cftr
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
EP3773721A4 (fr) Formulations d'immunoconjugué anti-cd79b stables
EP3755311A4 (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3426305A4 (fr) Compositions d'immunoglobulines anti-cd45 radio-marquées stabilisées
EP3883570A4 (fr) Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
EP3442488A4 (fr) Compositions pour l'application topique de composés
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
EP3941525A4 (fr) Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
MA54521A (fr) Dérivés d'oxopyridine substitués
MA51774A (fr) Dérivés de triazolopyrimidine destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
EP3890749A4 (fr) Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer